Local Coverage DeterminationAllergy/Immunology

LCD L32553: Allergy Immunotherapy — CGS

LCD-L32553

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L32553
Published
June 5, 2026
Effective date
November 7, 2024
MAC region
CGS Administrators

Summary

The new LCD on Allergy Immunotherapy may streamline billing processes and clarify coverage. This update will potentially enhance reimbursement rates for related procedures and codes, helping providers

New LCD may impact allergy immunotherapy billing.

Affected codes

ICD-10-CM

Affected specialty

Allergy/Immunology alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=32553&ver=21

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

Proposed LCD DL40050: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian

Policy LCD-DL40050 · Allergy/Immunology

High

The proposed Local Coverage Determination (LCD) on Allergen Immunotherapy may impact billing practices for providers offering subcutaneous immunotherapy. It could lead to higher reimbursement rates fo

View alert

Proposed LCD DL40052: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian

Policy LCD-DL40052 · Allergy/Immunology

High

The proposed LCD for Allergen Immunotherapy may significantly influence billing practices related to Subcutaneous Immunotherapy. Providers will need to ensure proper documentation and coding align wit

View alert

Proposed LCD DL40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — NGS

Policy LCD-DL40048 · Allergy/Immunology

High

The proposed LCD for Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) could have significant billing implications, particularly for allergists and practices specializing in immunoth

View alert

Proposed LCD DL39314: Off-Label Use of Intravenous Immune Globulin (IVIG) — NGS

Policy LCD-DL39314 · Allergy/Immunology

High

The proposed LCD addresses the billing implications for off-label uses of IVIG, which may affect reimbursement rates and eligibility for coverage under Medicare. Providers need to stay informed about

View alert